The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Evidence That 2-Arachidonoylglycerol but Not N-Palmitoylethanolamine or Anandamide Is the Physiological Ligand for the Cannabinoid CB2 Receptor
Open accessAbstract
We examined the effect of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand, on the intracellular free Ca(2+) concentrations in HL-60 cells that express the cannabinoid CB2 receptor. We found that 2-arachidonoylglycerol induces a rapid transient increase in intracellular free Ca(2+) concentrations in HL-60 cells. The response was affected by neither cyclooxygenase inhibitors nor lipoxygenase inhibitors, suggesting that arachidonic acid metabolites are not involved. Consistent with this notion, free arachidonic acid was devoid of any agonistic activity. Importantly, the Ca(2+) transient induced by 2-arachidonoylglycerol was blocked by pretreatment of the cells with SR144528, a CB2 receptor-specific antagonist, but not with SR141716A, a CB1 receptor-specific antagonist, indicating the involvement of the CB2 receptor but not the CB1 receptor in this cellular response. G(i) or G(o) is also assumed to be involved, because pertussis toxin treatment of the cells abolished the response. We further examined the structure-activity relationship. We found that 2-arachidonoylglycerol is the most potent compound among a number of naturally occurring cannabimimetic molecules. Interestingly, anandamide and N-palmitoylethanolamine, other putative endogenous ligands, were found to be a weak partial agonist and an inactive ligand, respectively. These results strongly suggest that the CB2 receptor is originally a 2-arachidonoylglycerol receptor, and 2-arachidonoylglycerol is the intrinsic natural ligand for the CB2 receptor that is abundant in the immune system.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Isolation and Structure of a Brain Constituent That Binds to the Cannabinoid Receptor
Devane, W. A., Hanuš, L., Breuer, A., Pertwee, R. G., Stevenson, L. A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A., & Mechoulam, R. (1992) · Science · doi:10.1126/science.1470919 · Cited by 5,633
Molecular characterization of a peripheral receptor for cannabinoids
Munro, S., Thomas, K. L., & Abu-Shaar, M. (1993) · Nature · doi:10.1038/365061a0 · Cited by 5,092
Structure of a cannabinoid receptor and functional expression of the cloned cDNA
Matsuda, L. A., Lolait, S. J., Brownstein, M. J., Young, A. C., & Bonner, T. I. (1990) · Nature · doi:10.1038/346561a0 · Cited by 5,011
Mechoulam, R., Ben-Shabat, S., Hanus, L., Ligumsky, M., Kaminski, N. E., Schatz, A. R., Gopher, A., Almog, S., Martin, B. R., Compton, D. R., et al. (1995) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)00109-d · Cited by 2,913
Determination and characterization of a cannabinoid receptor in rat brain
Devane, W. A., Dysarz, F. A., Johnson, M. R., Melvin, L. S., & Howlett, A. C. (1988) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09876-1 · Cited by 2,443
2-Arachidonoylgylcerol: A Possible Endogenous Cannabinoid Receptor Ligand in Brain
Sugiura, T., Kondo, S., Sukagawa, A., Nakane, S., Shinoda, A., Itoh, K., Yamashita, A., & Waku, K. (1995) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1995.2437 · Cited by 2,196
Self-citationSR141716A, a potent and selective antagonist of the brain cannabinoid receptor
Rinaldi-Carmona, M., Barth, F., Héaulme, M., Shire, D., Calandra, B., Congy, C., Martinez, S., Maruani, J., Néliat, G., Caput, D., et al. (1994) · FEBS Letters · doi:10.1016/0014-5793(94)00773-x · Cited by 1,757
Galiègue, S., Mary, S., Marchand, J., Dussossoy, D., Carrière, D., Carayon, P., Bouaboula, M., Shire, D., LE Fur, G., & Casellas, P. (1995) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1995.tb20780.x · Cited by 1,749
Formation and inactivation of endogenous cannabinoid anandamide in central neurons
Di Marzo, V., Fontana, A., Cadas, H., Schinelli, S., Cimino, G., Schwartz, J.-C., & Piomelli, D. (1994) · Nature · doi:10.1038/372686a0 · Cited by 1,587
A second endogenous cannabinoid that modulates long-term potentiation
Stella, N., Schweitzer, P., & Piomelli, D. (1997) · Nature · doi:10.1038/42015 · Cited by 1,496
Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action
Di Marzo, V., Melck, D., Bisogno, T., & De Petrocellis, L. (1998) · Trends in Neurosciences · doi:10.1016/s0166-2236(98)01283-1 · Cited by 712
SR 144528, the First Potent and Selective Antagonist of the CB2 Cannabinoid Receptor
Rinaldi-Carmona, M., Barth, F., Millan, J., Derocq, J.-M., Casellas, P., Congy, C., Oustric, D., Sarran, M., Bouaboula, M., Calandra, B., et al. (1998) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37266-0 · Cited by 709
Facci, L., Dal Toso, R., Romanello, S., Buriani, A., Skaper, S. D., & Leon, A. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.8.3376 · Cited by 632
Showalter, V. M., Compton, D. R., Martin, B. R., & Abood, M. E. (1996) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)20744-3 · Cited by 571
Varga, K., Wagner, J. A., Bridgen, D. T., & Kunos, G. (1998) · The FASEB Journal · doi:10.1096/fasebj.12.11.1035 · Cited by 410
Cadas, H., di Tomaso, E., & Piomelli, D. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-04-01226.1997 · Cited by 396
Schatz, A. R., Lee, M., Condie, R. B., Pulaski, J. T., & Kaminski, N. E. (1997) · Toxicology and Applied Pharmacology · doi:10.1006/taap.1996.8034 · Cited by 358
Felder, C. C., Nielsen, A., Briley, E. M., Palkovits, M., Priller, J., Axelrod, J., Nguyen, D. N., Richardson, J. M., Riggin, R. M., Koppel, G. A., et al. (1996) · FEBS Letters · doi:10.1016/0014-5793(96)00891-5 · Cited by 326
Prescott, S. M., & Majerus, P. W. (1983) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)33114-4 · Cited by 315
Bisogno, T., Berrendero, F., Ambrosino, G., Cebeira, M., Ramos, J. A., Fernandez-Ruiz, J. J., & Di Marzo, V. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.0254 · Cited by 312
Evidence That the Cannabinoid CB1 Receptor Is a 2-Arachidonoylglycerol Receptor
Sugiura, T., Kodaka, T., Nakane, S., Miyashita, T., Kondo, S., Suhara, Y., Takayama, H., Waku, K., Seki, C., Baba, N., et al. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.5.2794 · Cited by 310
Self-citationDi Marzo, V., Bisogno, T., De Petrocellis, L., Melck, D., Orlando, P., Wagner, J. A., & Kunos, G. (1999) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.1999.00631.x · Cited by 296
Bouaboula, M., Poinot‐Chazel, C., Marchand, J., Canat, X., Bourrié, B., Rinaldi‐Carmona, M., Calandra, B., Le Fur, G., & Casellas, P. (1996) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1996.0704p.x · Cited by 286
Lynn, A. B., & Herkenham, M. (1994) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)38654-4 · Cited by 276
Kaminski, N. E., Abood, M. E., Kessler, F. K., Martin, B. R., & Schatz, A. R. (1992) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09130-8 · Cited by 248
Schmid, P. C., Krebsbach, R. J., Perry, S. R., Dettmer, T. M., Maasson, J. L., & Schmid, H. H. O. (1995) · FEBS Letters · doi:10.1016/0014-5793(95)01194-j · Cited by 235
Sugiura, T., Kondo, S., Sukagawa, A., Tonegawa, T., Nakane, S., Yamashita, A., Ishima, Y., & Waku, K. (1996) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1996.0053h.x · Cited by 211
Self-citationThe peripheral cannabinoid receptor: adenylate cyclase inhibition and G protein coupling
Bayewitch, M., Avidor-Reiss, T., Levy, R., Barg, J., Mechoulam, R., & Vogel, Z. (1995) · FEBS Letters · doi:10.1016/0014-5793(95)01207-u · Cited by 210
MARZO, V. D., BISOGNO, T., SUGIURA, T., MELCK, D., & PETROCELLIS, L. D. (1998) · Biochemical Journal · doi:10.1042/bj3310015 · Cited by 199
Self-citationCarayon, P., Marchand, J., Dussossoy, D., Derocq, J.-M., Jbilo, O., Bord, A., Bouaboula, M., Galiègue, S., Mondière, P., Pénarier, G., et al. (1998) · Blood · doi:10.1182/blood.v92.10.3605 · Cited by 178
Berdyshev, E. V., Boichot, E., Germain, N., Allain, N., Anger, J.-P., & Lagente, V. (1997) · European Journal of Pharmacology · doi:10.1016/s0014-2999(97)01007-8 · Cited by 168
Cannabinoids enhance human B‐cell growth at low nanomolar concentrations
Derocq, J.-M., Ségui, M., Marchand, J., Le Fur, G., & Casellas, P. (1995) · FEBS Letters · doi:10.1016/0014-5793(95)00746-v · Cited by 167
Sugiura, T., Kodaka, T., Kondo, S., Tonegawa, T., Nakane, S., Kishimoto, S., Yamashita, A., & Waku, K. (1996) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1996.1757 · Cited by 164
Self-citationMunro, S. (1996) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(96)81598-7 · Cited by 154
Kondo, S., Kondo, H., Nakane, S., Kodaka, T., Tokumura, A., Waku, K., & Sugiura, T. (1998) · FEBS Letters · doi:10.1016/s0014-5793(98)00581-x · Cited by 147
Self-citationLee, M., Yang, K. H., & Kaminski, N. E. (1995) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)12097-1 · Cited by 144
Condie, R. B., Herring, A. C., Koh, W. S., Lee, M., & Kaminski, N. E. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.22.13175 · Cited by 133
Kaminski, N. E., Koh, W. S., Yang, K. H., Lee, M., & Kessler, F. K. (1994) · Biochemical Pharmacology · doi:10.1016/0006-2952(94)90588-6 · Cited by 132
Sugiura, T., Kodaka, T., Kondo, S., et al. (1997) · The Journal of Biochemistry · doi:10.1093/oxfordjournals.jbchem.a021838 · Cited by 129
Self-citationMcCoy, K. L., Matveyeva, M., Carlisle, S. J., & Cabral, G. A. (1999) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38313-2 · Cited by 116
Kempe, K. C., Hsu, F., Bohrer, A., & TURK, J. W. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.29.17287 · Cited by 114
Mechoulam, R., Fride, E., Ben‐Shabat, S., Meiri, U., & Horowitz, M. (1998) · European Journal of Pharmacology · doi:10.1016/s0014-2999(98)00777-8 · Cited by 107
Ouyang, Y., Hwang, S. G., Han, S. H., & Kaminski, N. E. (1998) · Molecular Pharmacology · doi:10.1124/mol.53.4.676 · Cited by 101
Klein, T., Kawakami, Y., Newton, C. A., & Friedman, H. P. (1991) · Journal of Toxicology and Environmental Health · doi:10.1080/15287399109531496 · Cited by 94
Fischer‐Stenger, K., Pettit, D. A. D., & Cabral, G. A. (1993) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)39607-2 · Cited by 82
Tetrahydrocannabinol inhibition of macrophage nitric oxide production
Coffey, R. G., Yamamoto, Y., Snella, E. M., & Pross, S. H. (1996) · Biochemical Pharmacology · doi:10.1016/0006-2952(96)00356-5 · Cited by 77
Low doses of anandamides inhibit pharmacological effects of delta 9-tetrahydrocannabinol.
Fride, E., Barg, J., Levy, R., Saya, D., Heldman, E., Mechoulam, R., & Vogel, Z. (1995) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)24465-2 · Cited by 75
Blanchard, D. K., Newton, C. A., Klein, T., Stewart, W. E., & Friedman, H. P. (1986) · International Journal of Immunopharmacology · doi:10.1016/0192-0561(86)90020-2 · Cited by 69
Zheng, Z., Specter, S. C., & Friedman, H. P. (1992) · International Journal of Immunopharmacology · doi:10.1016/0192-0561(92)90017-f · Cited by 62
Jbilo, O., Derocq, J., Ségui, M., Fur, G. L., & Casellas, P. (1999) · FEBS Letters · doi:10.1016/s0014-5793(99)00380-4 · Cited by 57
Hollister, L. E. (1992) · Journal of Psychoactive Drugs · doi:10.1080/02791072.1992.10471635 · Cited by 43
Marijuana and immunity: Tetrahydrocannabinol mediated inhibition of lymphocyte blastogenesis
Specter, S. C., Lancz, G. J., & Hazelden, J. (1990) · International Journal of Immunopharmacology · doi:10.1016/0192-0561(90)90081-w · Cited by 32
Cited by
International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors
Howlett, A. C., Barth, F., Bonner, T. I., Cabral, G., Casellas, P., Devane, W. A., Felder, C. C., Herkenham, M., Mackie, K., Martin, B. R., et al. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.2.161 · Cited by 2,819
Lo Verme, J., Fu, J., Astarita, G., La Rana, G., Russo, R., Calignano, A., & Piomelli, D. (2005) · Molecular Pharmacology · doi:10.1124/mol.104.006353 · Cited by 882
Cannabinoid CB2 receptors: immunohistochemical localization in rat brain
Gong, J.-P., Onaivi, E. S., Ishiguro, H., Liu, Q.-R., Tagliaferro, P. A., Brusco, A., & Uhl, G. R. (2006) · Brain Research · doi:10.1016/j.brainres.2005.11.035 · Cited by 820
Nonpsychotropic Cannabinoid Receptors Regulate Microglial Cell Migration
Walter, L., Franklin, A., Witting, A., Wade, C., Xie, Y., Kunos, G., Mackie, K., & Stella, N. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-04-01398.2003 · Cited by 665
Endocannabinoid signaling at the periphery: 50 years after THC
Maccarrone, M., Bab, I., Bíró, T., Cabral, G. A., Dey, S. K., Di Marzo, V., Konje, J. C., Kunos, G., Mechoulam, R., Pacher, P., et al. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.02.008 · Cited by 646
Metadata
- Authors
- Sugiura, T., Kondo, S., Kishimoto, S., Miyashita, T., Nakane, S., Kodaka, T., Suhara, Y., Takayama, H., & Waku, K.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2000-01
- Volume
- 275
- Issue
- 1
- Pages
- 605-612
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2089573633
- Cited by
- 371
- References
- 52
- FWCI
- 10.53
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.